Is Alexandria Real Estate Stock Underperforming the Nasdaq?

In this article:

Based in Pasadena, California, Alexandria Real Estate Equities, Inc. (ARE) is a leading real estate investment trust (REIT) that develops and manages campuses in key innovation markets across the U.S. Specializing in the life sciences sector, the company creates collaborative workspaces designed to foster research and development.

Companies valued at less than $10 billion are generally considered “mid-cap” stocks, and the REIT, with a market capitalization of $8.4 billion, fits perfectly into that category. Alexandria Real Estate Equities stands out due to its focused dominance in the highly specialized life sciences real estate sector, where it develops and leases complex lab and research facilities that are difficult to replicate. Its properties are concentrated in top innovation hubs like Boston and San Francisco, ensuring strong, sustained demand. The company benefits from long-term leases with high-quality biotech and pharmaceutical tenants, providing stable and predictable cash flows.

More News from Barchart

Alexandria Real Estate has been under significant pressure, with its shares currently trading at a steep 52.3% below their 52-week high of $101.21. Over the past three months, the stock has surged 2.9%, outpacing the broader Nasdaq Composite’s ($NASX) fall of 3.2% over the same time frame.

www.barchart.com
www.barchart.com

Over the past year, ARE has plunged 51.3%, and has dropped 43.7% over the past six months, sharply contrasting the S&P 500’s 26% and marginal rise over the same periods, respectively.

Technical indicators reinforce this bearish trend, as the stock has remained below its 200-day moving average for over a year and slipped under its 50-day moving average early this month.

www.barchart.com
www.barchart.com

On Feb. 10, Alexandria Real Estate Equities shares rose 1.2% after the company priced a $750 million public offering of 5.25% senior notes due 2036. The notes were issued at a slight discount with a 5.291% yield and are unsecured, backed by its subsidiary. ARE plans to use the proceeds primarily to repay existing debt tied to a prior tender offer, while temporarily allocating funds to short-term investments or general corporate purposes.